# Kenvue

Type: Company (KVUE)

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/kenvue
Canonical HTML page: https://getbiobrief.com/entity/kenvue

## Recent coverage (2 stories)

### 500+ Tylenol suits revived: $10B risk for Kenvue and OTC pharma
2026-07-25 19:56:51 · Sentiment: Negative · Impact: 7/10 · Sources: 2

The 2nd Circuit ruling revives mass tort litigation linking prenatal acetaminophen to autism, exposing Kenvue and retailers to billions in potential liability. The decision hinges on admissibility of novel scientific evidence, challenging Daubert standards and regulatory orthodoxy.
Full story: https://getbiobrief.com/story/tylenol-autism-lawsuits-revived-bio

### Scientific Studies Rebut RFK Jr. Claims on Vaccines, Tylenol, and SSRIs
2026-02-25 12:41:54 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Recent large-scale clinical studies are directly contradicting public health claims made by Robert F. Kennedy Jr. regarding the safety profiles of vaccines, acetaminophen, and antidepressants. These findings provide a critical scientific defense for pharmaceutical manufacturers facing increased regulatory scrutiny and litigation risks.
Full story: https://getbiobrief.com/story/scientific-studies-rebut-rfk-claims-pharma

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.